CYP1A1 and neoplasm: Cytotoxicity results indicate that trans-stilbenoid DMU212 (3,4,5,4′-tetramethoxystilbene) may be a potential tumour-selective anticancer agent with therapeutic potential for the treatment of CYP1 enzyme-expressing tumours (i.e., oestrogen-dependent tumours).